The research group led by Miyamoto found that DHT signaling via ARs upregulated EGFR and ERBB2 oncogenes [35], ELK1 [59], β-catenin [60], and ATF2 [61] in multiple human bladder cancer cell lines; downregulated levels of UDP-glucoronosyltransferases, a class of molecules that metabolizes and detoxifies carcinogens [31]; and downregulated the tumor suppressor FOXO1 [62]. This evidence concerns the gene EGFR and urinary bladder cancer.